Abstract 321P
Background
Ovarian cancer(OC) is the third most common gynaecological cancer in Indian according to Globocan 2020. The majority of patients are diagnosed in advanced stage III and IV. The aim of this study was to evaluate clinical epidemiology and survival outcomes in patients with epithelial ovarian cancer.
Methods
This was a retrospective analysis of patients with epithelial OC who were treated at Asian Institute of Medical Sciences from 1st January 2016 to 31st December 2020. Patient’s sociodemographic characteristics, clinicopathological details like the stage of cancer, treatment received and follow up details was extracted from medical records. All statistical analysis was performed using Microsoft Excel 2016 and R software (Rx 64 version 3.6.2). Survival was estimated by the Kaplan Meier method and compared by the log-rank test.
Results
251 OC patients records were evaluated, epithelial OC constituted 94%(n=235), with a median age 49 years. Majority 81%(n=190) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension 65%(n=153) and gastrointestinal disturbances including pain abdomen 45%(n=106). The most common histologic types were serous 76%(n=179) followed by mucinous carcinoma 18%(n=42). BRCA testing (germline and somatic) was performed in 80 patients. BRCA1/BRCA2 pathogenic or likely pathogenic variant was found in 25% (n=20) patients. Upfront cytoreductive surgery was done only in 28% (n=65). Interval cytoreductive surgery was done in 66%(n=155) patients. Median overall survival for the entire study cohort was 45 months (95% CI, 32 to 47.5). Median overall survival for stage I, II, III, and IV was 62, 53, 38 and 23 months, respectively.
Conclusions
Most of the patients presented in advanced stage of the disease and have poor outcome. Lack of awareness delayed presentation and late diagnosis are resulting in poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract